Statements (28)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:approvalYear |
2013
|
| gptkbp:ATCCode |
C02KX04
|
| gptkbp:brand |
gptkb:Opsumit
|
| gptkbp:CASNumber |
441798-33-0
|
| gptkbp:chemicalFormula |
C19H20Br2N6O4S
|
| gptkbp:contraindication |
pregnancy
severe hepatic impairment |
| gptkbp:form |
gptkb:tablet
|
| gptkbp:genericName |
macitentan
|
| https://www.w3.org/2000/01/rdf-schema#label |
Opsumit
|
| gptkbp:indication |
pulmonary arterial hypertension
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:manufacturer |
gptkb:Actelion_Pharmaceuticals
|
| gptkbp:mechanismOfAction |
endothelin receptor antagonist
|
| gptkbp:pregnancyCategory |
gptkb:X_(US)
|
| gptkbp:prescriptionRequired |
https://www.opsumit.com/
|
| gptkbp:riskFactor |
teratogenicity
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
gptkb:anemia
bronchitis headache urinary tract infection nasopharyngitis liver enzyme elevation |
| gptkbp:status |
FDA approved
|
| gptkbp:bfsParent |
gptkb:Actelion
|
| gptkbp:bfsLayer |
6
|